Dana-Farber's Lowe Center for Thoracic Oncology
@DFarberThoracic
Followers
190
Following
30
Media
14
Statuses
79
Patient-centered care, clinical trials, and translational research for #lungcancer #thoracic @DanaFarber
Boston
Joined May 2024
Highlighting this important study from our very own Dr. @Jia_Luo
In a study, published in @CCR_AACR, @danafarber researcher @Jia_Luo uncovered the potential for underdiagnosis of NUT carcinoma and identified additional tests required for an accurate diagnosis. Read more: https://t.co/aTG77Sh7TL
0
1
4
We're this close to hitting our fundraising goal💙 Help Team Lung Cancer finish strong in the #JimmyFundWalk on Oct. 5. Your support fuels lung cancer research & care at Dana-Farber. Walk with us or donate today! 🔗 https://t.co/FDPSq4ZS3N
#LungCancerAwareness #CloseToGoal
0
2
5
CAR-T in #SCLC ! Dr. @sands_jacob of @DFarberThoracic shows early signals in SCLC with LB2102. Thanks to our #ImmuneEffectorCell solid tumor group for their help with this study! #DAVALung #lcsm #lcam #HawaiiLung25 @SclcSMASHERS
0
5
22
Great video coming out of our EGFR Center!
Check out this clip featuring Center Faculty Drs. Pasi Jänne and @JuliaRotow in conversation about updates from @ASCO 2025 related to #EGFR-mutant #lungcancer! #lcsm #NSCLC Watch the full conversation here: https://t.co/cjFD7syeET
0
1
6
The Chen-Huang Center for EGFR-Mutant Lung Cancers’ webpage was created to offer resources specifically for patients diagnosed with an #EGFR mutation: https://t.co/WVQTFeVmr2
#LCSM #CancerResearch
0
4
13
Join us tomorrow in the Hall C tomorrow @ASCO @ASCOTECAG @HemOncFellows @hemeoncfellow @DFarberThoracic #ASCO25
0
5
21
At #AACR25, @Jia_Luo, MD, @DanaFarber presents a late-breaking abstract on the clinical activity of daraxonrasib in KRAS mutant non-small cell lung cancer (#NSCLC), finding early clearance in circulating tumor DNA predicted partial response or stable disease.
1
7
26
⭐ Alice T. Shaw, MD, PhD, of @DFarberThoracic, @DanaFarber, has received the @AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research at #AACR25! 👏 Congratulations, Dr. Shaw! ➡️ Learn more: https://t.co/70Q3gslPET
0
1
4
In a new study published in @CCR_AACR, @DanaFarber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. @DFarberThoracic Read more: https://t.co/GIjAvnNQT7
1
15
46
Congratulations to the AACR Scientific Achievement Awardees, including our own Dr. Alice Shaw.
Congratulations to Matthew Meyerson, MD, PhD, FAACR, @DrChoueiri, and Alice T. Shaw, MD, PhD, recipients of @AACR 2025 Scientific Achievement Awards. @DanaFarber Read more here: https://t.co/eJzRT7DvnC
1
2
15
🎉 Big news our #equalstudy is officially OPEN! 🧬 Hear from our ctDNA Program Manager, Courtney Mantz, as she introduces this groundbreaking study using a simple blood test to possibly detect EGFR+ lung cancer. 👥 Are you 40+ and identify as Hispanic/Latinx or East/Southeast
2
10
18
We’re proud to be named on of Newsweek’s Greatest Workplaces for Women. This recognition reflects our commitment to fostering an inclusive and empowering workplace for all. https://t.co/F9xJ90bRdj
rankings.newsweek.com
Newsweek is partnering with Plant-A Insights Group to spotlight America's Greatest Workplaces for Women 2025. These companies are committed to creating equit...
1
6
20
DFCI Thoracic Oncology Team at #TTLC25! @IASLC @JuliaRotow @sands_jacob @Jia_Luo @NarjustFlorezMD @DavidBarbie8
0
5
21
🚀 Experts vs AI: The ADC Challenge – Lung Cancer Edition 🧠🤖 ADCs are revolutionizing #lungcancer treatment—but can #AI keep up with expert oncologists? Find out in this interactive, CME-accredited satellite symposium! 📅 Today at #TTLC25 🔗 Register now:
1
8
14
Masterful presentation by Dr. @JuliaRotow discussing the ever expanding #EGFR mt #NSCLC. How do we measure the cost of intensifying 1L treatment, and how will we navigate the numerous upcoming options in the 2L space? #lcam #lcsm #TTLC25 @EGFRResisters @EGFRSummit @EgfrUk @IASLC
0
11
30
We’re thrilled to celebrate our own @NarjustFlorezMD for being recognized as a Rising Star Women Leader in Healthcare 2025 by Women We Admire! 🌟🏆 This honor highlights her passion, innovation, and dedication to mentoring the next generation of healthcare leaders.
3
5
27
📰 ICYMI: A project led by @DavidBarbie8 of @DFarberThoracic, @DanaFarber is the first to receive the @IASLC @lcrf_org Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: https://t.co/LS9wbbN5In
#lcsm #LCAM #LungCancer
2
8
26
Very excited to announce the launch of the Center for RAS Therapeutics, led by Dr. Andy Aguirre and our own Dr. Alice Shaw, a thoracic oncologist in our group.
We’re thrilled to announce the launch of Center for RAS Therapeutics to target the RAS oncogene in cancer. The first of its kind Center aims to advance new treatment approaches for patients with RAS mutant cancers. Learn more: https://t.co/gamUtXX9kO
2
3
26
📰 ICYMI: A project led by @DavidBarbie8 of @DFarberThoracic, @DanaFarber is the first to receive the @IASLC @lcrf_org Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: https://t.co/LS9wbbN5In
#lcsm #LCAM #LungCancer
0
3
6
EGFR mutations are the most common actionable mutations in lung cancer, found in ~15% of cases. On average, people with EGFR lung cancer are: - Younger at diagnosis. - More likely to be women. - More likely to have Asian Ancestry. - Less likely to have a history of heavy
2
24
59